Natural histories of chronic obstructive pulmonary disease

Proceedings of the American Thoracic Society

Volumn 5, Issue 9, 2008, Pages 878-883

  Rennard, Stephen I ^a   Vestbo, Jørgen ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b HVIDOVRE HOSPITAL   (Denmark)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomarkers; Lung function; Severity; Symptoms

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HISTORY OF MEDICINE; LUNG FUNCTION; SYMPTOM;

AGING; DISEASE PROGRESSION; FORCED EXPIRATORY VOLUME; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SMOKING;

EID: 57349167572     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200804-035QC     Document Type: Article

References (63)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD, 2006 [Internet]. (Accessed 29 Aug 2008) Bethesda (MD): NHLBI.
2. Fletcher C, Peto R, Tinker C, Speizer F. The natural history of chronic bronchitis and emphysema. New York: Oxford University Press; 1976.
3. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977;1:1645-1648.
4. Benowitz NL, Jacob P III. Individual differences in nicotine kinetics and metabolism in humans. NIDA Res Monogr 1997;173:48-64.
5. Mazzone RW, Kornblau S. Size of pores of Kohn: influence of transpulmonary and vascular pressures. J Appl Physiol 1981;51:739-745.
6. Parra SC, Gaddy LR, Takaro T. Ultrastructural studies of canine interalveolar pores (of Kohn). Lab Invest 1978;38:8-13.
7. Verbeken EK, Cauberghs M, Mertens I, Clement J, Lauweryns JM, Van de Woestijne KP. The senile lung: comparison with normal and emphysematous lungs. 2. Functional aspects. Chest 1992;101:800-809.
8. Verbeken EK, Cauberghs M, Mertens I, Lauweryns JM, Van de Woestijne KP. Tissue and airway impedance of excised normal, senile, and emphysematous lungs. J Appl Physiol 1992;72:2343-2353.
9. O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006;3:180-184.
10. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006;367:1216-1219.
11. Burrows B, Knudson RJ, Cline MG, Lebowitz MD. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis 1977;115:195-205.
12. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-1689.
13. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003;58:388-393.
14. Marsh S, Aldington S, Shirtcliffe P, Weatherall M, Beasley R. Smoking and COPD: what really are the risks? Eur Respir J 2006;28:883-884.
15. Niewoehner D. Structure-function relationships: the pathophysiology of airflow obstruction. In: Stockley R, Rennard SI, Rabe K, Celli B, editors. Chronic obstructive pulmonary disease. Malden, MA: Blackwell; 2007. pp. 3-19.
16. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
17. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996;153:1530-1535.
18. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
19. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002;20:799-805.
20. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
21. Islam SS, Schottenfeld D. Declining FEV1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. Cancer Epidemiol Biomarkers Prev 1994;3:289-298.
22. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, Dosman J, Macklem PT. The relations between structural changes in small airways and pulmonary function tests. N Engl J Med 1978;298:1277-1281.
23. Nagai A, West WW, Thurlbeck WM. The National Institutes of Health intermittent positive-pressure breathing trial: pathology studies II. Correlation between morphologic findings, clinical findings, and evidence of expiratory airflow obstruction. Am Rev Respir Dis 1985;132:946-953.
24. Hale KA, Ewing SL, Gosnell BA, Niewoehner DE. Lung disease in long-term smokers with and without chronic airflow obstruction. Am Rev Respir Dis 1984;130:716-721.
25. Mitchell RS, Stanford RE, Johnson JM, Silvers GW, Dart G, George MS. The morphologic features of the bronchi, bronchioles and alveoli in chronic airway obstruction: a clinicopathologic study. Am Rev Respir Dis 1976;114:137-145.
26. Shapiro SD, Snider GL, Rennard SI. Chronic bronchitis and emphysema. In: Mason RJ, Broadus VC, Murray JF, Nadel JA, editor. Textbook of respiratory medicine, 4th ed. Philadelphia: Elsevier; 2005. pp. 1115-1167.
27. Silverman EK. Progress in chronic obstructive pulmonary disease genetics. Proc Am Thorac Soc 2006;3:405-408.
28. Sandford AJ, Joos L, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002;8:87-94.
29. Patel B, Make B, Coxson HO, Muller NL, Pillai S, Anderson W, Silverman E, Lomas D. Airway and parenchymal disease in chronic obstructive pulmonary disease are distinct phenotypes. Proc Am Thorac Soc 2006;3:533.
30. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-679.
31. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, Postma DS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur Respir J 2005; 26:835-845.
32. Spurzem JR, Romberger DJ, Manouilova LS, Stoner J, Hepp L, Minton R, Vessey R, Horstman D, Rennard SI. Smoking cessation is followed by an increase in T lymphocytes recovered by bronchoalveolar lavage (BAL) in COPD [abstract]. Proc Am Thorac Soc 2006;3:A628.
33. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax 2006;61:935-939.
34. Burrows B. An overview of obstructive lung diseases. Med Clin North Am 1981;65:455-471.
35. 1 by age and smoking status: facts, figures, and fallacies. Thorax 1997;52:820-827.
36. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 2007;370:758-764.
37. 1/vital capacity ratio: a longitudinal population study from childhood to adulthood. Am J Respir Crit Care Med 2002;165:1480-1488.
38. Weiss ST, Ware JH. Overview of issues in the longitudinal analysis of respiratory data. Am J Respir Crit Care Med 1996;154:S208-S211.
39. Barker DJP, Godfrey KM, Fall CHD, Osmond C, Winter PD, Shaheen SO. Relation of birthweight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991;303:671-675.
40. Shaheen SO, Sterne JA, Florey CD. Birth weight, childhood lower respiratory tract infection, and adult lung function. Thorax 1998;53:549-553.
41. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-887.
42. Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107(5, Suppl):187S-193S.
43. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1992;85(Suppl B):25-31. [Discussion, p. 33237.]
44. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, Macnee W, Jones P, Pride N, Rodriguez-Roisin R, et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005;99:1546-1554.
45. Wegner RE, Jorres RA, Kirsten DK, Magnussen H. Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994;7:725-729.
46. Ries AL, Kaplan RM, Blumberg E. Use of factor analysis to consolidate multiple outcome measures in chronic obstructive pulmonary disease. J Clin Epidemiol 1991;44:497-503.
47. Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. Development of a COPD severity score. Curr Med Res Opin 2006;22:1679-1687.
48. Ries AL, Kaplan RM, Limberg TM, Prewitt LM. Effects of pulmonary rehabilitation of physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995;122:823-832.
49. Ries AL, Bauldoff GS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, Zuwallack R, Herrerias C. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007; 131(5, Suppl):4S-42S.
50. Council MR. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: Report of the Medical Research Council Working Party. Lancet 1981;1:681-686.
51. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-398.
52. Rennard S, Carrera M, Agusti AG. Management of chronic obstructive pulmonary disease: are we going anywhere? Eur Respir J 2000;16:1035-1036.
53. Agusti A. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Proc Am Thorac Soc 2007;4:522-525.
54. Rennard SI. Chronic obstructive pulmonary disease: linking outcomes and pathobiology of disease modification. Proc Am Thorac Soc 2006;3:276-280.
55. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005;26:142-153.
56. Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD. Trends Pharmacol Sci 2007;28:544-550.
57. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008;31:204-212.
58. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-1959.
59. Ashley F, Kannel WB, Sorlie PD, Masson R. Pulmonary function: relation to aging, cigarette habit, and mortality. Ann Intern Med 1975;82:739-745.
60. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
61. Tzortzaki EG, Lambiri I, Vlachaki E, Siafakas NM. Biomarkers in COPD. Curr Med Chem 2007;14:1037-1048.
62. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 2006;7:74.
63. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE. Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2006;19:189-199.